Literature DB >> 28560549

Cost Analysis of Prostate Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) in the Treatment of Benign Prostatic Hyperplasia.

Sandeep Bagla1,2, John Smirniotopoulos3, Julie Orlando4, Rachel Piechowiak4.   

Abstract

PURPOSE: Prostatic arterial embolization (PAE) has emerged as a minimally invasive alternative to TURP; however, there are limited cost comparisons reported. The purpose of this study was to compare in-hospital direct costs of elective PAE and TURP in a hospital setting.
MATERIALS AND METHODS: Institutional Review Board-approved retrospective review was performed on patients undergoing PAE and TURP from January to December 2014. Inclusion criteria included male patients greater than 40 years of age who presented for ambulatory TURP or PAE with no history of prior surgical intervention for BPH. Direct costs were categorized into the following categories: nursing and operating room or interventional room staffing, operating room or interventional supply costs, anesthesia supplies, anesthesia staffing, hospital room cost, radiology, and laboratory costs. Additionally, length of stay was evaluated for both groups.
RESULTS: The mean patient age for the TURP (n = 86) and PAE (n = 70) cohorts was 71.3 and 64.4 years, respectively (p < 0.0001). Intra-procedural supplies for PAE were significantly more costly than TURP ($1472.77 vs $1080.84, p < 0.0001). When including anesthesia supplies and nursing/staffing, costs were significantly more expensive for TURP than PAE ($2153.64 vs $1667.10 p < 0.0001). The average length of stay for the TURP group was longer at 1.38 versus 0.125 days for the PAE group. Total in-hospital costs for the TURP group ($5338.31, SD $3521.17) were significantly higher than for PAE ($1678.14, SD $442.0, p < 0.0001).
CONCLUSIONS: When compared to TURP, PAE was associated with significantly lower direct in-hospital costs and shorter hospital stay.

Entities:  

Keywords:  BPH; Cost; Prostate artery embolization (PAE); TURP

Mesh:

Year:  2017        PMID: 28560549     DOI: 10.1007/s00270-017-1700-7

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  13 in total

1.  Reasons to consider prostatic artery embolization.

Authors:  Dominik Abt; Hans-Peter Schmid; Mark J Speakman
Journal:  World J Urol       Date:  2021-02-10       Impact factor: 4.226

Review 2.  Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Peng Xiang; Di Guan; Zhen Du; Yongxiu Hao; Wei Yan; Yonghui Wang; Yutong Liu; Dan Liu; Hao Ping
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

3.  Prostatic Artery Embolization: Indications, Preparation, Techniques, Imaging Evaluation, Reporting, and Complications.

Authors:  Ubenicio Silveira Dias; Maurício Ruettimann Liberato de Moura; Publio Cesar Cavalcante Viana; André Moreira de Assis; Antônio Sérgio Zanfred Marcelino; Airton Mota Moreira; Claudia Costa Leite; Giovanni Guido Cerri; Francisco Cesar Carnevale; Natally Horvat
Journal:  Radiographics       Date:  2021-08-20       Impact factor: 6.312

Review 4.  Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Karen Ann McCutcheon; Michael Borofsky; Shamar Young; Jafar Golzarian; Myung Ha Kim; Vikram M Narayan; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

Review 5.  Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.

Authors:  Juan Va Franco; Jae Hung Jung; Mari Imamura; Michael Borofsky; Muhammad Imran Omar; Camila Micaela Escobar Liquitay; Shamar Young; Jafar Golzarian; Areti Angeliki Veroniki; Luis Garegnani; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-07-15

Review 6.  Use of angioembolization in urology: a review.

Authors:  Kirkpatrick B Fergus; Nima Baradaran; Anas Tresh; Miles B Conrad; Benjamin N Breyer
Journal:  Transl Androl Urol       Date:  2018-08

7.  Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial.

Authors:  Dominik Abt; Lukas Hechelhammer; Gautier Müllhaupt; Stefan Markart; Sabine Güsewell; Thomas M Kessler; Hans-Peter Schmid; Daniel S Engeler; Livio Mordasini
Journal:  BMJ       Date:  2018-06-19

8.  In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial.

Authors:  Gautier Müllhaupt; Lukas Hechelhammer; Daniel S Engeler; Sabine Güsewell; Patrick Betschart; Valentin Zumstein; Thomas M Kessler; Hans-Peter Schmid; Livio Mordasini; Dominik Abt
Journal:  BJU Int       Date:  2019-01-28       Impact factor: 5.588

9.  Prostatic Artery Embolization for Benign Prostatic Hyperplasia: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-06-04

10.  Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Karen Ann McCutcheon; Michael Borofsky; Shamar Young; Jafar Golzarian; Balaji Reddy; Tae Young Shin; Myung Ha Kim; Vikram Narayan; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2020-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.